579
IRUS Total
Downloads
  Altmetric

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

File Description SizeFormat 
Gut 2nd resubmission.pdfAccepted version5.17 MBAdobe PDFView/Open
Title: The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
Authors: Mullish, BH
Quraishi, MN
Segal, J
McCune, VL
Baxter, M
Marsden, GL
Moore, D
Colville, A
Bhala, N
Iqbal, TH
Settle, C
Kontkowski, G
Hart, AL
Hawkey, PM
Goldenberg, SD
Williams, HRT
Item Type: Journal Article
Abstract: Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the United Kingdom (UK) have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. Whilst the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.
Issue Date: 8-Oct-2018
Date of Acceptance: 1-Jul-2018
URI: http://hdl.handle.net/10044/1/61310
DOI: https://dx.doi.org/10.1136/gutjnl-2018-316818
ISSN: 0017-5749
Publisher: BMJ Publishing Group
Start Page: 1920
End Page: 1941
Journal / Book Title: Gut
Volume: 67
Copyright Statement: © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.
Sponsor/Funder: Medical Research Council
Medical Research Council (MRC)
Imperial College Healthcare NHS Trust- BRC Funding
Funder's Grant Number: MR/R00875/1
MR/R000875/1
RDA27
Keywords: Science & Technology
Life Sciences & Biomedicine
Gastroenterology & Hepatology
ACTIVE ULCERATIVE-COLITIS
PUMP INHIBITOR THERAPY
TERM-FOLLOW-UP
INTESTINAL MICROBIOTA
GUT MICROBIOTA
OPEN-LABEL
INSULIN SENSITIVITY
BOWEL PREPARATION
FROZEN INOCULUM
NATIONAL-SURVEY
colonic microflora
enteric bacterial microflora
infective colitis
inflammatory bowel disease
intestinal microbiology
Anti-Bacterial Agents
Clostridium Infections
Clostridium difficile
Fecal Microbiota Transplantation
Gastroenterology
Gastrointestinal Tract
Humans
Recurrence
Societies, Medical
Tissue Donors
United Kingdom
Gastrointestinal Tract
Humans
Clostridium difficile
Clostridium Infections
Recurrence
Anti-Bacterial Agents
Gastroenterology
Tissue Donors
Societies, Medical
Fecal Microbiota Transplantation
United Kingdom
Gastroenterology & Hepatology
1103 Clinical Sciences
1114 Paediatrics and Reproductive Medicine
Publication Status: Published
Online Publication Date: 2018-08-28
Appears in Collections:Department of Surgery and Cancer